Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling-Reference-Cited by-同舟云学术

Summary of the 2019 Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Published:2020-10 Issue:10 Volume:26 Page:e247-e255
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Holstein Sarah A.,Howard Alan,Avigan David,Bhutani Manisha,Cohen Adam D.,Costa Luciano J.,Dhodapkar Madhav V.,Gay Francesca,Gormley Nicole,Green Damian J.,Hillengass Jens,Korde Neha,Li Zihai,Mailankody Sham,Neri Paola,Parekh Samir,Pasquini Marcelo C.,Puig Noemi,Roodman G. David,Samur Mehmet Kemal,Shah Nina,Shah Urvi A.,Shi Qian,Spencer Andrew,Suman Vera J.,Usmani Saad Z.,McCarthy Philip L.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference65 articles.

1. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: summary and recommendations from the organizing committee;Holstein;Biol Blood Marrow Transplant,2018

2. Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling;Holstein;Biol Blood Marrow Transplant,2019

3. Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling;Holstein;Biol Blood Marrow Transplant,2020

4. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016

5. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition;Stetler-Stevenson;Cytometry B Clin Cytom,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis;Clinical Lymphoma Myeloma and Leukemia;2023-05

2. MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials;Blood;2023-02-09

3. Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma;Transplantation and Cellular Therapy;2022-08

4. The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma;Transplantation and Cellular Therapy;2021-10

5. Future Directions in Maintenance Therapy in Multiple Myeloma;Journal of Clinical Medicine;2021-05-24